Pasithea Therapeutics Opens Second Ketamine Therapy Clinic in the United Kingdom
22 December 2021 - 12:00AM
Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the
“Company”), a novel biotechnology company focused on the research
and discovery of new and effective treatments for psychiatric and
neurological disorders, today announced that its wholly owned
subsidiary, Pasithea Clinics, has opened its second London clinic
in Marylebone offering intravenous (“IV”) ketamine therapy to
patients suffering from treatment-resistant mental health issues.
The Company opened its first U.K. clinic in Knightsbridge in
October 2021.
“Through our second London clinic, we are
pleased to increase access to this important therapy for patients
in the U.K. with treatment-resistant mental health disorders,”
stated Dr. Tiago Reis Marques, CEO of Pasithea Therapeutics. “More
than ever, new treatment therapies are urgently needed for these
patients and by broadening our coverage, we can work to close the
treatment gap.”
“Two decades of research supports the efficacy
of ketamine in improving symptoms experienced in some mental health
disorders. With the opening of our Marylebone location, we are
expanding our footprint in the U.K. and will continue to work
toward bringing this treatment option to patients nationwide,” said
Dr. Yassine Bendiabdallah, Managing Director of Pasithea Clinics in
the U.K.
Ketamine is a U.S. Food and Drug Administration
(“FDA”) approved drug introduced to the medical community as an
anesthetic more than 50 years ago. It has recently been repurposed
for the treatment of psychiatric disorders using significantly
lower doses than in anesthesia and is gaining ground as a promising
treatment for mental health disorders. In certain psychiatric
conditions, such as treatment-resistant depression (“TRD”) and
post-traumatic stress disorder (“PTSD”), it has shown remarkable
efficacy and a rapid and sustained effect.
Major Depression is the leading cause of
long-term disability worldwide, according to the World Health
Organization, with existing treatments having limited success
rates, numerous side effects and onset of action delayed by several
weeks. Studies have shown that up to 70% of those who receive IV
ketamine treatment can eventually show a clinical response. While
the number of treatments suggested is done on a case-by-case basis,
a typical treatment plan consists of up to six infusions in the
interval of two to three weeks.
About Pasithea Therapeutics Corp.
Pasithea Therapeutics Corporation is a U.S.
biotechnology company focused on the research and discovery of new
and effective treatments for psychiatric and neurological
disorders. With an experienced team of experts in the fields of
neuroscience and psychopharmacology, Pasithea is developing new
molecular entities for the treatment of psychiatric and
neurological disorders. Pasithea is also focused on addressing the
needs of patients currently suffering with mental illness by
providing access to IV ketamine infusions both in clinics and
in-home settings.
Forward Looking Statements
This press release contains statements that
constitute “forward-looking statements.” Forward-looking statements
are subject to numerous conditions, many of which are beyond the
control of the Company. While the Company believes these
forward-looking statements are reasonable, undue reliance should
not be placed on any such forward-looking statements, which are
based on information available to the Company on the date of this
release. These forward-looking statements are based upon current
estimates and assumptions and are subject to various risks and
uncertainties, including, without limitation, those set forth in
the Company’s filings with the SEC. Thus, actual results could be
materially different. The Company undertakes no obligation to
update these statements whether as a result of new information,
future events or otherwise, after the date of this release, except
as required by law.
Pasithea Therapeutics Corp. Company ContactDr.
Tiago Reis MarquesChief Executive OfficerE: tiago@pasithea.com
Pasithea Therapeutics Corp. Investor
RelationsLisa M. WilsonIn-Site Communications, Inc.T:
212-452-2793E: lwilson@insitecony.com
Pasithea Therapeutics (NASDAQ:KTTAW)
Historical Stock Chart
From Jun 2024 to Jul 2024
Pasithea Therapeutics (NASDAQ:KTTAW)
Historical Stock Chart
From Jul 2023 to Jul 2024